贝利木单抗靶向治疗系统性红斑狼疮的研究进展

Belimumab： targeted therapy for systemic lupus erythematosus

系统性红斑狼疮是一种系统性自身免疫性疾病,确切的发病机制尚未完全清楚,B细胞的异常激活是系统性红斑狼疮发病过程中的关键环节,B细胞激活因子对于B细胞的异常激活至关重要.贝利木单抗是一种人源化单克隆抗体,可选择性识别、阻止血清中游离B淋巴细胞刺激因子.贝利木单抗对系统性红斑狼疮的疗效和安全性在随机、双盲、大规模的临床试验中得到肯定,其疗效高、不良反应少、耐受性高,是一种有发展前景的治疗系统性红斑狼疮的生物制剂.

Systemic lupus erythematosus （SLE） is a systemic autoimmune disease,whose exact pathogenesis is not fully clear as yet.The abnormal activation of B cells plays an important role in the development of SLE,and B cell-activating factor （BAFF） is critical for the abnormal activation of B cells.Belimumab is a human monoclonal antibody which can selectively recognize and block soluble BAFF.The efficacy and safety of belimumab have been confirmed for the treatment of SLE in randomized,double-blind,large-scale clinical trials.As a biological agent with high efficacy,few side effects and high tolerability,belimumab is a promising drug for SLE.